About SYGNIS
Data last updated:
SYGNIS is a company based in Madrid (Spain) founded in 1997. It operates as a B2B. SYGNIS has completed 4 acquisitions, including CBS Scientific, Expedeon and Innova Biosciences. SYGNIS operates in a competitive market with competitors including Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
- Headquarter Madrid, Spain
- SectorsHealthcare
- PhoneLocked
- WebsiteLocked
- Jurisdiction Bangalore North, Karnataka, India
- Annual Revenue$403.09 K (USD)19.31as on Mar 31, 2022
- Net Profit$26.11 K (USD)-14.87as on Mar 31, 2022
- EBITDA$31.2 K (USD)28.43as on Mar 31, 2022
- Latest Funding Round$2.38 M (USD), Debt – Conventional
May 09, 2018
- InvestorsNot available
- Employee CountNot available
- Investments & AcquisitionsCBS Scientific
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of SYGNIS
Investments & Acquisitions by SYGNIS
SYGNIS has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include CBS Scientific, Expedeon and Innova Biosciences.
Investment portfolio details for SYGNIS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
Reagents and kits for protein-based research are developed and supplied. | Locked | Locked | 2003 | Locked | |
Antibody labeling and bioconjugation kits are developed and marketed. | Locked | Locked | 2002 | Locked | |
Specializes in immunoassay technology | Locked | Locked | 2001 | Locked |
Complete acquisition details for SYGNIS
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SYGNIS
Detailed financials for SYGNIS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sygnis Comparisons
Peer comparison for SYGNIS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SYGNIS
SYGNIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked | Biological reagents and antibodies are developed for life science research. | |
| Locked | Locked | Locked | Developer of cell culture media and ancillary reagents for life science research | |
| Locked | Locked | Locked | Proteins, antibodies, and molecular tools are manufactured for research applications. | |
| Locked | Locked | Locked | Research services, reagents, and kits for biotech applications are provided. | |
| Locked | Locked | Locked | Molecular diagnostic device and kits | |
| Locked | Locked | Locked | Molecular biology reagents and kits are supplied for research applications. |
Detailed competitors of SYGNIS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sygnis
Complete news archive for SYGNIS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SYGNIS
SYGNIS was founded in 1997 and raised its 1st funding round 11 years after it was founded.
SYGNIS is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
Annual revenue of SYGNIS is $403.09K as on Mar 31, 2022.
SYGNIS, based in Madrid, focuses on providing healthcare solutions, advancing biotech innovations, life sciences, and reagents and supplies. SYGNIS provides molecular biology reagents for research and laboratory applications. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
SYGNIS's top competitors include Abcam, Meridian Bioscience and Stem Cell Technologies.
SYGNIS has made 4 acquisitions, including CBS Scientific, Expedeon, and Innova Biosciences.